SA PRO
Free Account
AN2 Therapeutics, Inc.ANTXNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 83% recommend buying.

Consensus Rating
Buy
6 analysts·Limited coverage
83%
Rating Distribution
Strong Buy
00%
Buy
583%
Hold
117%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 618% higher.

Bear Case
$2.00
+85%
Consensus
$7.75
+618%
Bull Case
$22.00
+1937%
Price Range6 analysts
Low
Consensus
High
$2.00
$22.00
Current Target
Current Price
$1.08
Upside to Target
$6.67

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

May 5, 2025JMP Securities
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
Target:$2.00
+66.7%from $1.20
Jul 3, 2024Leerink Partners
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
Target:$5.00
+134.7%from $2.13
May 16, 2024Evercore ISI
AN2 Therapeutics (ANTX) PT Lowered to $2 at Evercore ISI
Target:$2.00
-11.9%from $2.27
Apr 2, 2024JMP Securities
JMP Securities Upgrades AN2 Therapeutics (ANTX) to Market Outperform
Target:$6.00
+59.6%from $3.76
Nov 14, 2022Leerink Partners
SVB Leerink Maintains Outperform on AN2 Therapeutics, Lowers Price Target to $25
Target:$25.00
+68.1%from $14.87
Apr 19, 2022Evercore ISI
Evercore ISI Group Initiates Coverage On AN2 Therapeutics with Outperform Rating, Announces Price Target of $25
Target:$25.00
+78.6%from $14.00
Apr 19, 2022Oppenheimer
Oppenheimer Initiates Coverage On AN2 Therapeutics with Outperform Rating, Announces Price Target of $22
Target:$22.00
+49.5%from $14.72

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance